ArticleJournal of the American Heart Association2022
Outcome of Antibody-Mediated Fetal Heart Disease With Standardized Anti-Inflammatory Transplacental Treatment.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Echogenicities in the Fetal Heart: Echocardiographic Evaluation, Differential Diagnosis and Clinical Outcomes.Pediatric cardiology · 2026Review
- Discordant Manifestation of Congenital Heart Block in a Twin Pregnancy: A Case Report.Diagnostics (Basel, Switzerland) · 2026Article
- Reversal of evolving third-degree atrioventricular block in utero by early detection and combination therapy.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2026Article
- Ambulatory Fetal Heart Rate and Rhythm Monitoring for Pregnancies at Risk for Fetal Arrhythmias: Perspectives from the Fetal Heart Society.Pediatric cardiology · 2026Review
- Neonatal lupus erythematosus: an acquired autoimmune disease to be taken seriously.Annals of medicine · 2025Review
- Effects of maternal anti-Ro/La antibodies on fetal atrioventricular conduction evaluated with echocardiography: a state-of-the-art review.Archives of gynecology and obstetrics · 2025Review
- Intrauterine Diagnosis and Treatment of High-Grade Atrioventricular Block: A Case Series and Literature Review.Clinical case reports · 2025Article
- Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block.Acta obstetricia et gynecologica Scandinavica · 2024Article
- Article
- Diagnosis and Management of Fetal Arrhythmias in the Current Era.Journal of cardiovascular development and disease · 2024Review
- Monitoring of Women with Anti-Ro/SSA and Anti-La/SSB Antibodies in Germany-Status Quo and Intensified Monitoring Concepts.Journal of clinical medicine · 2024Article
- Perivascular Basal Echogenicity in the Fetal Heart: An Unconventional Marker of Maternal Autoimmune Antibodies.Pediatric cardiology · 2024Article
- Article
- Endocardial Fibroelastosis as an Independent Predictor of Atrioventricular Valve Rupture in Maternal Autoimmune Antibody Exposed Fetus: A Systematic Review with Clinicopathologic Analysis.Diagnostics (Basel, Switzerland) · 2023Review
- Reversal of Fetal Heart Block in Antibody-Positive Mother After Hydroxychloroquine and Dexamethasone.Pediatric cardiology · 2023Article
- Fetal Arrhythmia Diagnosis and Pharmacologic Management.Journal of clinical pharmacology · 2022Review
- To Be or Not to Be: Surviving Immune-Mediated Fetal Heart Disease.Journal of the American Heart Association · 2022Article
- To Be or Not to Be Treated: That Is the Question in Managing a Fetus With Cardiac Injury Exposed to Anti-SSA/Ro.Journal of the American Heart Association · 2022Article
- A review of neonatal lupus syndrome.Science progressReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Transplacental fetal treatment of immune-mediated fetal heart disease, including third-degree atrioventricular block (AVB III) and endocardial fibroelastosis, is controversial. Methods and Results To study the impact of routine transplacental fetal treatment, we reviewed 130 consecutive cases, including 108 with AVB III and 22 with other diagnoses (first-degree/second-degree atrioventricular block [n=10]; isolated endocardial fibroelastosis [n=9]; atrial bradycardia [n=3]). Dexamethasone was started at a median of 22.4 gestational weeks. Additional treatment for AVB III included the use of a β-agonist (n=47) and intravenous immune globulin (n=34). Fetal, neonatal, and 1-year survival rates with AVB III were 95%, 93%, and 89%, respectively. Variables present at diagnosis that were associated with perinatal death included an atrial rate <90 beats per minute (odds ratio [OR], 258.4; 95% CI, 11.5-5798.9;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.